Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

By The Northwire Desk — AI Analysis Jun 08, 2026 · 07:31 TRIP · 0.04 Red Light Holland Corp.
TRIP · Price

Executive Summary

  • Filament Health (a subsidiary of Red Light Holland) has signed an agreement with GHU Paris Psychiatrie & Neurosciences to supply its patented botanical psilocybin drug candidate, PEX010.
  • The supply supports the "KETAPSYCHECOG" academic clinical study, a randomized, double-blinded, cross-over trial in healthy volunteers designed to compare the behavioral and neural effects of psilocybin and ketamine.
  • This agreement expands Filament's international clinical research footprint into France and highlights PEX010's role in over 80 global studies, reinforcing the Company's focus on GMP-compliant, standardized psychedelic research supply.

Key Details

  • Agreement Counterparties: Filament Health and GHU Paris Psychiatrie & Neurosciences (a leading French university hospital group specializing in mental health and central nervous system disorders).
  • Product Supplied: PEX010, Filament's patented, GMP-compliant, standardized, naturally derived botanical psilocybin drug candidate.
  • Study Name & Design: "KETAPSYCHECOG: Effects of ketamine and psilocybin on behavioral and neural measures: a randomized, double blinded, cross-over study in healthy volunteers."
  • Study Purpose: Compare behavioral and neural effects of psilocybin and ketamine; PEX010 will be supplied for the psilocybin component to characterize how naturally derived psilocybin acts on the brain, complementing patient-population trials.
  • Strategic Impact: Adds France to Filament's international clinical research footprint and supports Red Light Holland's commitment to providing a quality-controlled, regulatory-conscious supply framework for psychedelic research.
  • PEX010 Global Footprint: Currently supplied to more than 80 clinical studies worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.
  • Corporate Context: The announcement follows Red Light Holland's recent acquisition of Filament Health, which expanded the Company's pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities.
Read the original news release →

More from Red Light Holland Corp.

Jun 18, 2026 · 09:02

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

Other Jun 04, 2026 · 07:32

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings May 08, 2026 · 07:31

Red Light Holland Validates Filament Acquisition with Cocaine Trial Data, Yet Dilution Risks Loom

Other